Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The TrkB+ cancer stem cells contribute to post-chemotherapy recurrence of triple-negative breast cancers in an orthotopic mouse model.

Yin B, Ma ZY, Zhou ZW, Gao WC, Du ZG, Zhao ZH, Li QQ.

Oncogene. 2015 Feb 5;34(6):761-70. doi: 10.1038/onc.2014.8. Epub 2014 Feb 17.

PMID:
24531713
2.

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.

Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL.

J Clin Invest. 2013 Mar;123(3):1348-58. doi: 10.1172/JCI65416. Epub 2013 Feb 8.

3.

Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.

Burnett JP, Lim G, Li Y, Shah RB, Lim R, Paholak HJ, McDermott SP, Sun L, Tsume Y, Bai S, Wicha MS, Sun D, Zhang T.

Cancer Lett. 2017 May 28;394:52-64. doi: 10.1016/j.canlet.2017.02.023. Epub 2017 Feb 27.

PMID:
28254410
4.

Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer.

Zhang D, Sun B, Zhao X, Ma Y, Ji R, Gu Q, Dong X, Li J, Liu F, Jia X, Leng X, Zhang C, Sun R, Chi J.

Mol Cancer. 2014 Sep 8;13:207. doi: 10.1186/1476-4598-13-207.

5.

Brain-derived neurotrophic factor (BDNF)-induced tropomyosin-related kinase B (Trk B) signaling is a potential therapeutic target for peritoneal carcinomatosis arising from colorectal cancer.

Tanaka K, Okugawa Y, Toiyama Y, Inoue Y, Saigusa S, Kawamura M, Araki T, Uchida K, Mohri Y, Kusunoki M.

PLoS One. 2014 May 6;9(5):e96410. doi: 10.1371/journal.pone.0096410. eCollection 2014.

6.

Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: differential expression of neurotrophic and gliotrophic factors.

Song F, Bandara M, Deol H, Loeb JA, Benjamins J, Lisak RP.

J Neuroimmunol. 2013 Sep 15;262(1-2):11-8. doi: 10.1016/j.jneuroim.2013.05.012. Epub 2013 Jun 12.

7.

A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer.

Kaur S, Elkahloun AG, Singh SP, Chen QR, Meerzaman DM, Song T, Manu N, Wu W, Mannan P, Garfield SH, Roberts DD.

Oncotarget. 2016 Mar 1;7(9):10133-52. doi: 10.18632/oncotarget.7100.

8.

A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.

Park YH, Jung HH, Do IG, Cho EY, Sohn I, Jung SH, Kil WH, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH.

Int J Cancer. 2015 Apr 15;136(8):1976-84. doi: 10.1002/ijc.29233. Epub 2014 Dec 24.

10.

Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway.

Li T, Zhang Q, Zhang J, Yang G, Shao Z, Luo J, Fan M, Ni C, Wu Z, Hu X.

BMC Cancer. 2014 Feb 16;14:96. doi: 10.1186/1471-2407-14-96.

11.

BDNF: An Oncogene or Tumor Suppressor?

Radin DP, Patel P.

Anticancer Res. 2017 Aug;37(8):3983-3990. Review.

PMID:
28739680
12.

Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.

Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC.

Clin Cancer Res. 2013 May 15;19(10):2723-33. doi: 10.1158/1078-0432.CCR-12-2986. Epub 2013 Apr 2.

13.

Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.

Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, Conzen SD.

Clin Cancer Res. 2013 Nov 15;19(22):6163-72. doi: 10.1158/1078-0432.CCR-12-3826. Epub 2013 Sep 9.

14.

Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1.

Choi DS, Blanco E, Kim YS, Rodriguez AA, Zhao H, Huang TH, Chen CL, Jin G, Landis MD, Burey LA, Qian W, Granados SM, Dave B, Wong HH, Ferrari M, Wong ST, Chang JC.

Stem Cells. 2014 Sep;32(9):2309-23. doi: 10.1002/stem.1746.

15.

The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair.

Liang DH, Choi DS, Ensor JE, Kaipparettu BA, Bass BL, Chang JC.

Cancer Lett. 2016 Jul 1;376(2):249-58. doi: 10.1016/j.canlet.2016.04.002. Epub 2016 Apr 6.

16.

Effects of Chinese medicinal herbs on expression of brain-derived Neurotrophic factor (BDNF) and its interaction with human breast cancer MDA-MB-231 cells and endothelial HUVECs.

Chiu JH, Chen FP, Tsai YF, Lin MT, Tseng LM, Shyr YM.

BMC Complement Altern Med. 2017 Aug 12;17(1):401. doi: 10.1186/s12906-017-1909-7.

17.

Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.

Samanta D, Gilkes DM, Chaturvedi P, Xiang L, Semenza GL.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5429-38. doi: 10.1073/pnas.1421438111. Epub 2014 Dec 1.

18.

Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.

Kim EM, Mueller K, Gartner E, Boerner J.

J Surg Res. 2013 Nov;185(1):231-9. doi: 10.1016/j.jss.2013.06.041. Epub 2013 Jul 17.

PMID:
23899511
19.

Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells.

Qiu M, Peng Q, Jiang I, Carroll C, Han G, Rymer I, Lippincott J, Zachwieja J, Gajiwala K, Kraynov E, Thibault S, Stone D, Gao Y, Sofia S, Gallo J, Li G, Yang J, Li K, Wei P.

Cancer Lett. 2013 Jan 28;328(2):261-70. doi: 10.1016/j.canlet.2012.09.023. Epub 2012 Oct 3.

PMID:
23041621
20.

Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.

Bernemann C, Hülsewig C, Ruckert C, Schäfer S, Blümel L, Hempel G, Götte M, Greve B, Barth PJ, Kiesel L, Liedtke C.

Mol Cancer. 2014 Jul 17;13:174. doi: 10.1186/1476-4598-13-174.

Supplemental Content

Support Center